OX-640 is under clinical development by Orexo and currently in Phase I for Anaphylaxis. According to GlobalData, Phase I drugs for Anaphylaxis have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OX-640’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OX-640 overview

Epinephrine is under development for the treatment of allergic reactions, including anaphylaxis. It is administered through nasal route in the form of powder. The drug candidate acts by targeting alpha and beta-adrenergic receptors. It is being developed based on amorphOX platform.

Orexo overview

Orexo is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company’s commercial product portfolio consists of Abstral, Edluar, and Zubsolv. The company develops its products based on its proprietary drug delivery technology, namely, sublingual tablet technology. The sublingual tablet rapidly disintegrates and dissolves, allowing the medicine to be directly absorbed into the bloodstream through the mucous membrane. It also carries out the industrial-scale production of pharmaceutical products. Orexo collaborates with various pharmaceutical companies to advance and commercialize its products. Orexo is headquartered in Uppsala, Sweden.

For a complete picture of OX-640’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.